Xenikos, a private, clinical-stage biopharmaceutical company, is focused on developing innovative immunotherapies, based on toxin-conjugated antibodies, which are designed to quickly and safely reset the immune system in patients with a severe immune disease or post-transplantation rejection. Xenikos’ flagship product, T-Guard®, has entered Phase 3 testing for the treatment of acute graft-versus-host disease (aGVHD).
